XML 26 R9.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Braeburn License | 6 Months Ended
--- | ---
Jun. 30, 2018
Braeburn License [Abstract] |
Braeburn License [Text Block] |
| 5. | Braeburn License
Until its termination in May 2018, we were party to a license agreement (as amended, the “License Agreement”) pursuant to which we had granted Braeburn Pharmaceuticals, Inc. (“Braeburn”) the exclusive commercialization rights to Probuphine in the United States and its territories and Canada. Under the License Agreement, we received certain milestone payments, as well as royalties on net sales of Probuphine. Upon receipt of approval, our obligation was fulfilled and we recognized as revenue the full amount of the milestone payment. In addition, we were entitled to receive a low single digit royalty on sales by Braeburn of other competing continuous delivery treatments for opioid dependence as defined in the License Agreement. The License Agreement provided for us to be reimbursed by Braeburn for any development services and activities undertaken at Braeburn’s request. Under ASC 606, there was no change in the amount or timing of revenue recognized under this agreement. In February 2016, Braeburn sublicensed rights to develop and commercialize Probuphine in Canada to Knight Therapeutics, Inc. (“Knight”). On May 25, 2018, we entered into a Termination and Transition Services Agreement (the “Transition Agreement”) with Braeburn pursuant to which we regained all rights to the commercialization and clinical development of Probuphine in the United States and Canada. Braeburn paid us $1.0 million, transferred inventory to us with a value of approximately $1.1 million and agreed to provide support services through December 28, 2018. In addition, the Transition Agreement provides for the immediate transfer to us of all regulatory documentation and development data related to Probuphine. The estimated fair value of the inventory received was determined using available inputs such as existing supply agreements, prior selling prices and remaining life to expiration. We recognized approximately $2.1 million of license related revenue related to this transaction in the three month period ended June 30, 2018. The sublicense to Knight was assigned to Titan as part of the Transition Agreement.

X
- Definition Braeburn license. + References No definition available. + Details
Name: | ttnp_LicenseRightsDisclosureAbstract
Namespace Prefix: | ttnp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License rights disclosure. + References No definition available. + Details
Name: | ttnp_LicenseRightsDisclosureTextBlock
Namespace Prefix: | ttnp_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration